CanagliflozinThird Party Manufacturing in India

Canagliflozin works by selectively and reversibly inhibiting sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubules of the kidneys. SGLT2 is the primary transporter responsible for reabsorbing the majority of filtered glucose from the renal tubular lumen back into the bloodstream. By blocking this transporter, Canagliflozin lowers the renal threshold for glucose filtration and prevents its reabsorption. This directly promotes the excretion of excess glucose in the urine, leading to a significant reduction in plasma glucose levels. Because this mechanism of action is completely independent of insulin secretion and pancreatic beta-cell function, it carries a low risk of hypoglycemia. Additionally, the urinary excretion of glucose creates an osmotic diuresis and a loss of calories. This osmotic diuretic effect helps lower blood pressure and reduces intraglomerular pressure, which contributes to long-term cardiovascular protection and slows the progression of diabetic nephropathy. Unlike traditional oral hypoglycemics, Canagliflozin provides multi-organ benefits. It is highly effective and well-tolerated for adults with type 2 diabetes.

Therapeutic Uses

Canagliflozin is prescribed for the treatment of:

• Type 2 Diabetes Mellitus: Improves glycemic control in adults as an adjunct to diet and exercise, either as monotherapy or combined with metformin.
• Cardiovascular Risk Reduction: Prevents major adverse cardiovascular events, including heart attacks, strokes, and cardiovascular death in patients with established heart disease.
• Diabetic Nephropathy: Retards the progression of kidney disease, reducing the risk of end-stage renal failure, doubling of serum creatinine, and renal death.
• Weight and Blood Pressure Management: Provides secondary benefits by promoting weight loss and lowering blood pressure via caloric excretion and mild diuresis.

Why Manufacturers Choose Canagliflozin

Canagliflozin has emerged as a high-demand therapeutic agent in the global antidiabetic segment. With the growing prevalence of type 2 diabetes and a clinical shift toward medications that offer cardioprotective and renoprotective benefits, Canagliflozin's prescription volume has grown substantially.

For pharmaceutical marketers and distributors, Canagliflozin (available in 100mg and 300mg tablets) offers high therapeutic value and excellent profit margins. Its complex synthesis and regulatory interest make it a premium product for WHO-GMP third-party manufacturing, satisfying strict quality criteria for both domestic PCD franchises and export markets.